Wessman steps down as Actavis CEO

Robert Wessman has stepped down as the CEO of Actavis Group to put greater focus on his investment company, Salt Investments. Wessman will continue to serve on the Actavis board. The new CEO is Sigurdur Oli Olafsson, former deputy CEO.

Marinus Pharmaceuticals has appointed John Krayacich as president and CEO.

Regado Biosciences announced the appointment of David J. Mazzo, Ph.D., as president and CEO.

Catalent Pharma Solutions has named George Fotiades as its new interim president and CEO.

Questcor Pharmaceuticals announced that George Stuart will be transitioning from his position as senior vice president of finance and CFO once a successor joins the company.

Sucampo Pharmaceuticals said CFO Mariam E. Morris has resigned. Chief Accounting Officer Jan Smilek will serve as acting finance chief.

Regulus Therapeutics has appointed Garry Menzel, Ph.D., as executive vice president of corporate development and finance.

INC Research named Nick Kenny, Ph.D. as the senior vice president of oncology.

Panacea Pharmaceuticals has appointed Suzanne Sensabaugh as vice president, regulatory affairs.

Anacor Pharmaceuticals announced that it has appointed Kurt Jarnagin, Ph.D., as its vice president of biological research.

SAFC has named Tom Beil as vice president of quality and regulatory affairs.

Celera has named Jean Amos Wilson, Ph.D., as vice president of laboratory operations at Berkeley HeartLab.

ARCA biopharma has appointed James Carr, PharmD, as vice president of marketing.

ChemGenex Pharmaceuticals Limited named Jean-Luc Tétard to its board of directors.

Pervasis Therapeutics named Frank Litvack, M.D., to its board of directors.
 
Ligand Pharmaceuticals announced that Stephen L. Sabba, M.D., has been elected to its board of directors.
 
Pluristem Therapeutics announced that Brian H. Annex, M.D. has accepted an appointment to the company's Scientific Advisory Board.

Suggested Articles

Voyager stands to receive up to $728 million in milestones for each compound AbbVie chooses to advance beyond phase 1.

A UCSF team found that Type 1 diabetes starts with "secretory senescence," a process whereby DNA damage causes beta cells to stop working properly.

Japanese pharma Daiichi Sankyo is looking to boost its research focus with a series of changes across its R&D.